1.96
price down icon2.00%   -0.04
after-market アフターアワーズ: 1.96
loading
前日終値:
$2.00
開ける:
$2
24時間の取引高:
500.94K
Relative Volume:
0.53
時価総額:
$70.39M
収益:
$832.00K
当期純損益:
$-135.12M
株価収益率:
-0.3218
EPS:
-6.09
ネットキャッシュフロー:
$-124.69M
1週間 パフォーマンス:
-6.22%
1か月 パフォーマンス:
-14.04%
6か月 パフォーマンス:
-77.18%
1年 パフォーマンス:
-62.95%
1日の値動き範囲:
Value
$1.905
$2.04
1週間の範囲:
Value
$1.90
$2.06
52週間の値動き範囲:
Value
$1.74
$14.75

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Name
名前
Inovio Pharmaceuticals Inc
Name
セクター
Healthcare (1183)
Name
電話
(858) 410-3134
Name
住所
6769 MESA RIDGE RD., SAN DIEGO, PA
Name
職員
122
Name
Twitter
@inoviopharma
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
INO's Discussions on Twitter

INO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
INO
Inovio Pharmaceuticals Inc
1.96 70.39M 832.00K -135.12M -124.69M -6.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.32 120.86B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
710.00 77.62B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
646.64 39.62B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
276.19 35.50B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.61 28.20B 3.30B -501.07M 1.03B -2.1146

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-05-14 開始されました Stephens Overweight
2024-01-25 アップグレード Oppenheimer Perform → Outperform
2022-11-09 ダウングレード Maxim Group Buy → Hold
2022-11-01 ダウングレード BofA Securities Neutral → Underperform
2022-07-19 再開されました RBC Capital Mkts Sector Perform
2022-05-11 ダウングレード Oppenheimer Outperform → Perform
2022-01-21 アップグレード BofA Securities Underperform → Neutral
2021-12-29 再開されました Jefferies Hold
2021-09-10 ダウングレード BofA Securities Neutral → Underperform
2021-06-24 開始されました Jefferies Hold
2021-03-23 開始されました BofA Securities Neutral
2021-02-12 開始されました Oppenheimer Outperform
2020-11-17 ダウングレード ROTH Capital Neutral → Sell
2020-11-10 アップグレード ROTH Capital Sell → Neutral
2020-09-28 ダウングレード Cantor Fitzgerald Overweight → Neutral
2020-09-28 アップグレード Maxim Group Hold → Buy
2020-07-01 ダウングレード Maxim Group Buy → Hold
2020-07-01 ダウングレード ROTH Capital Neutral → Sell
2020-06-29 ダウングレード H.C. Wainwright Buy → Neutral
2020-06-26 ダウングレード Stifel Buy → Hold
2020-05-21 開始されました The Benchmark Company Buy
2020-04-30 ダウングレード ROTH Capital Buy → Neutral
2020-03-13 ダウングレード Piper Sandler Overweight → Neutral
2020-03-13 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2019-12-19 開始されました ROTH Capital Buy
2018-02-15 繰り返されました Maxim Group Buy
2017-10-18 開始されました RBC Capital Mkts Outperform
2017-09-06 開始されました Citigroup Buy
2017-06-08 アップグレード Piper Jaffray Neutral → Overweight
2017-05-24 繰り返されました Maxim Group Buy
2017-03-16 アップグレード Maxim Group Hold → Buy
2017-03-16 ダウングレード Piper Jaffray Overweight → Neutral
すべてを表示

Inovio Pharmaceuticals Inc (INO) 最新ニュース

pulisher
05:27 AM

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

05:27 AM
pulisher
01:24 AM

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $12.40 Average Price Target from Brokerages - MarketBeat

01:24 AM
pulisher
01:14 AM

Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $12.40 - Defense World

01:14 AM
pulisher
12:06 PM

DNA Nanotechnology Market Overall Study Report 2025-2032 | - openPR

12:06 PM
pulisher
Feb 06, 2025

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Feb 06, 2025
pulisher
Feb 05, 2025

BlackRock, Inc. Expands Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com

Feb 05, 2025
pulisher
Feb 05, 2025

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Feb 05, 2025
pulisher
Feb 04, 2025

Anal Cancer Market Forecast 2034: Clinical Trials, Medication, - openPR

Feb 04, 2025
pulisher
Feb 04, 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

INOVIO Reports Inducement Grant Under Inducement Plan - GuruFocus.com

Feb 03, 2025
pulisher
Feb 03, 2025

Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

Feb 03, 2025
pulisher
Feb 01, 2025

INOVIO to Present at Oppenheimer Healthcare Life Sciences Conference - MyChesCo

Feb 01, 2025
pulisher
Jan 31, 2025

Vanguard Group Inc. Reduces Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com

Jan 31, 2025
pulisher
Jan 30, 2025

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - StreetInsider.com

Jan 30, 2025
pulisher
Jan 29, 2025

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Jan 29, 2025
pulisher
Jan 29, 2025

INOVIO's Next Big Move: CEO Reveals Future of DNA Medicine at Major Healthcare Conference - StockTitan

Jan 29, 2025
pulisher
Jan 28, 2025

Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Jan 28, 2025
pulisher
Jan 27, 2025

Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch

Jan 27, 2025
pulisher
Jan 25, 2025

Head to Head Review: Inovio Pharmaceuticals (NASDAQ:INO) and Hypertension Diagnostics (OTCMKTS:HDII) - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

INOVIO Reports Promising Long-Term Data for INO-3107 in Treating RRP - MSN

Jan 24, 2025
pulisher
Jan 22, 2025

Inovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s Bullish - MSN

Jan 22, 2025
pulisher
Jan 22, 2025

Barclays PLC Buys 25,116 Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World

Jan 22, 2025
pulisher
Jan 20, 2025

INOVIO Targets 2025 as Transformational Year with Major Progress on INO-3107 - MSN

Jan 20, 2025
pulisher
Jan 16, 2025

What is HC Wainwright’s Estimate for INO FY2024 Earnings? - Defense World

Jan 16, 2025
pulisher
Jan 14, 2025

Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock? - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

Inovio Pharmaceuticals (NASDAQ:INO) Given New $3.00 Price Target at HC Wainwright - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Anal Cancer Market on Track for Major Expansion by 2034, - openPR

Jan 13, 2025
pulisher
Jan 13, 2025

Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $3.00 by Analysts at HC Wainwright - MarketBeat

Jan 13, 2025
pulisher
Jan 12, 2025

JMP Securities Reaffirms “Market Outperform” Rating for Inovio Pharmaceuticals (NASDAQ:INO) - Defense World

Jan 12, 2025
pulisher
Jan 11, 2025

Inovio Pharmaceuticals' SWOT analysis: dna-based immunotherapy firm faces hurdles - Investing.com Australia

Jan 11, 2025
pulisher
Jan 11, 2025

Inovio Pharmaceuticals' SWOT analysis: dna-based immunotherapy firm faces hurdles By Investing.com - Investing.com South Africa

Jan 11, 2025
pulisher
Jan 10, 2025

Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $11.50 - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Inovio Pharmaceuticals' (INO) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat

Jan 10, 2025
pulisher
Jan 09, 2025

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accom - GuruFocus.com

Jan 09, 2025
pulisher
Jan 09, 2025

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments - Longview News-Journal

Jan 09, 2025
pulisher
Jan 08, 2025

What's Going On With Inovio Pharmaceuticals (INO) Stock? - Benzinga

Jan 08, 2025
pulisher
Jan 07, 2025

Why Inovio Pharmaceuticals (INO) Stock Is Skyrocketing - Benzinga

Jan 07, 2025
pulisher
Jan 01, 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares Purchased by State Street Corp - Defense World

Jan 01, 2025
pulisher
Dec 30, 2024

Inovio Pharmaceuticals Q3 Earnings Tops Estimates, Lifts Retail Sentiment - MSN

Dec 30, 2024
pulisher
Dec 27, 2024

Inovio Completes Enrollment In The Phase 1 U.S. Trial Of Ino-4800 For Covid-19 Dna Vaccine Interim Results Expected In June - Reuters

Dec 27, 2024

Inovio Pharmaceuticals Inc (INO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$74.13
price down icon 1.09%
$20.11
price down icon 2.71%
$347.71
price down icon 1.71%
$4.69
price down icon 6.94%
biotechnology ONC
$223.50
price down icon 2.35%
$117.61
price down icon 1.94%
大文字化:     |  ボリューム (24 時間):